Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Income - Net (2023 - 2025)

Guided Therapeutics (GTHP) has disclosed Interest Income - Net for 3 consecutive years, with -$157000.0 as the latest value for Q2 2025.

  • Quarterly Interest Income - Net fell 109.33% to -$157000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$546000.0 through Jun 2025, down 100.0% year-over-year, with the annual reading at -$378000.0 for FY2024, 38.97% down from the prior year.
  • Interest Income - Net hit -$157000.0 in Q2 2025 for Guided Therapeutics, down from -$147000.0 in the prior quarter.
  • In the past five years, Interest Income - Net ranged from a high of -$61000.0 in Q1 2024 to a low of -$157000.0 in Q2 2025.
  • Historically, Interest Income - Net has averaged -$95400.0 across 3 years, with a median of -$73000.0 in 2023.
  • Biggest five-year swings in Interest Income - Net: rose 7.58% in 2024 and later tumbled 140.98% in 2025.
  • Year by year, Interest Income - Net stood at -$66000.0 in 2023, then plummeted by 103.03% to -$134000.0 in 2024, then dropped by 17.16% to -$157000.0 in 2025.
  • Business Quant data shows Interest Income - Net for GTHP at -$157000.0 in Q2 2025, -$147000.0 in Q1 2025, and -$134000.0 in Q4 2024.